Table 1.

Characteristics of the patients included in the study

IDAge (y)Clinical stageTarget lesions (mm)Tumor histologyClinical responseNo. involved nodesEstrogen receptor statusProgesterone receptor statusErbB2
J-0451IIIb90.0DY0++
I-0267IIIa82.0DY0++
I-0358IIIa120.0DY0++
I-0556IIIa150.0DNNA+
I-0663IIIb85.7DY0+
I-0739IIIb98.0DY6+++
I-0944IIIb120.0DY19+++
I-1032IIIa390.0DYNA+
I-1548IIIb92.0DY3
I-1655IIIa116.0D/LY9+++
I-1837IIIa148.0DY2++
I-1960IIIa82.0DN5+++
I-2048IIIa109.0DY4+++
I-2154IIIa120.0MY0+++
I-2243IIIa102.0DN16+++
I-2363IIIa112.0CY14
I-2456IIb80.0DY3++
I-2546IIIa140.0DY0+
I-3651IIIa71.0DY4++
I-3434IIIa115.0LY16++
Q-06 1364IIIb130.0PN2++
Q-2840IIIb110.0DN21+++
Q-3265IIa40.0DY0+
Q-4746IIb45.0DY0+
Q-4855IIa35.0DY0+++
Q-2757IIIa45.0DY2++
Q-4449IIIb70.0DY17+
Q-454651IIIb48.0DY3+++
Q-1764IIIb40.0DY1++
Q-10053IIa30.0DY2++
Q-10467IIIb110.0DN17++
Q-10731IIIa65.0DY9+++
Q-12933IV120.0DY0
Q-11356IIIb35.0LY2+
Q-11540IIIb45.0DY5+++
Q-12747IIIa60.0DN1+
Q-13047IIa30.0DY1++
Q-13655IIIa60.0DY7++
J-11 (V)42IIIa70.0DY0
I-33 (V)61IIIa95.0DNNA
Q-144 (V)45IIIa85.0AY23ND
Q-52 (V)56IIa35.0DY0+++
J-01 (V)39IIIb59.0DY3++
I-31 (V)45IIIa138.0LY5++
Q-138 (V)42IIIb50.0DY6+++
Q-170 (V)42IIa50.0DY1+++
Q-164 (V)58IIIb35.0DY1++
Q-183 (V)47IV100.0DYNA++
J-15 (V)48IIIb60.0DYNA+
I-01 (V)42IIIa110.0DN4+
J-03 (V)47IIIb60.0DY6++
  • Note: Estrogen receptor, progesterone receptor, and ErbB2 were determined by immunohistochemistry: +, positive; −, negative.

    Abbreviations: V, validation set; ND, not determined; NA, not available; clinical response: Y, yes; N, no; tumor histology: D, ductal; L, lobular; D/L, mixed ductal and lobular; C, cribriform; P, papillary; M, medullary; A, apocrine.